In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived from the HER-2/neu Protooncogene Protein

Cancer Research

Volumn 54, Issue 4, 1994, Pages 1071-1076

  Disis, Mary L ^a   Smith, Joseph W ^a   Murphy, Ann E ^a   Chen, Wei ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; TUMOR ANTIGEN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL SPECIFICITY; CELLULAR IMMUNITY; CYTOLYSIS; HELPER CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTO ONCOGENE; REPRODUCIBILITY;

AMINO ACID SEQUENCE; BINDING SITES; EPITOPES; HLA-A2 ANTIGEN; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0028330866     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Fefer, A., Jr., Einstein, A. Cheever, M., and Berenson, J. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann. NY Acad. Sci., 276: 573-583, 1976.
2. Greenberg, P. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ T cells: cytolytic T cells can mediate eradication of disseminated leukemia. J. Immunol., 136: 1917-1922, 1986.
3. Greenberg, P., Kern, D., and Cheever, M. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-+2-T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med., 161: 1122-1134, 1985.
4. Shu, S., and Rosenberg, R. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res., 45: 1657-1662, 1985.
5. Cheever, M., Greenberg, P., and Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol., 125: 711-714, 1980.
6. Cheever, M., Greenberg, P., and Fefer, A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin-2. J. Immunol., 726: 1318-1322, 1981.
7. Riddell, S., Watanabe, K., Goodrich, J., Li, C., Agha, M., and Greenberg, P. Restoration of viral immunity in immunocompromised humans by the adoptive transfer of T cell clones. Science (Washington DC), 257: 238-241, 1992.
8. Jerome, K., Barnd, D., Bendt, K., Boyer, C., Taylor-Papdimitriou, J., McKenzie, I., Bast, R., Jr., and Finn, O. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51: 2908-2916, 1991.
9. Boon, T. Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res., 58: 177-210, 1992.
10. Ioannides, C., loannides, M., and O'Brian, C. T cell recognition of oncogene products: a new strategy for immunotherapy. Mol. Carcinog., 6: 77-82, 1992.
11. Chen, W., Peace, D., Rovira, D., You, S., and Cheever, M. T cell immunity to the joining region of p. 10bcri, h' protein. Proc. Natl. Acad. Sci. USA, 89: 1468-1472, 1992.
12. Peace, D., Chen, W., Nelson, H., and Cheever, M. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol., 146: 2059-2065, 1991.
13. Disis, M.L., Calenoff, E., McLaughlin, G., Murphy, A.E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., Livingston, R.B., Moe, R., and Cheever, M.A. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
14. Coussens, L., Yang-Feng, T.L., Chen, Y.L.E., Gray, A., McGrath, J., Seeburg, P.H., Liberman, T.A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1985.
15. Paik, S., Hazan, R., Fisher, E., Sass, R., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M., and King, C. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-s protein overexpression in primary breast cancer. J. Clin. Oncol., 8: 103-112, 1990.
16. Toikkanen, S., Helin, H., Isola, J., and Joensuu, H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J. Clin. Oncol., 10: 1044-1048, 1992.
17. Allred, D., Clark, G., Molina, R., Tandon, A., Schnitt, S., Gilchrist, K., Osborne, C., Tormey, D., and McGuire, W. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol., 23: 974-979, 1992.
18. Milligan, G., Morrison, L., Gorka, J., Braciale, V., and Braciale, T. The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen. J. Immunol., 145: 3188-3193, 1990.
19. Kallioniemi, O., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L.C., Smith, H., Wald-man, R., Pinkel, D., and Gray, J. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA, 89: 5321-5325, 1992.
20. Kerns, B., Pence, J., Huper, G., Kinney, R., and Iglehart, J. c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. J. Histochem. Cytochem., 38: 1823-1830, 1990.
21. Press, M., Cordon-Cardo, C., and Slamon, D. Expression of HER-2/neu proto-onco-gene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
22. Natali, P., Nicotra, M., Bigotti, A., Venturo, I., Slamon, D., Fendly, B., and Ullrich, A. Expression of the p. 85 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer, 45: 457-461, 1990.
23. Gusterson, B., Gelber, R., Goldhirsch, A., Price, K., Save-Soderborgh, J., Anbazha-gan, R., Styles, J., Rudenstam, C., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A., Bürki, K., Castiglione, M., Collins, J., Lindtner, J., and Senn, H.J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
24. Slamon, D., Godolphin, W., Jones, L., Holt, J., Wong, S., Keith, D., Levine, W., Stuart, S., Udove, J., Ullrich, A., and Press, M. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
25. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.), 351: 290-296, 1991.
26. Zhou, X., Berg, L., Motal, U., and Jondal, M. In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. J. Immunol. Methods, 153: 193-200, 1992.
27. Ishioka, G., Colon, S., Miles, C., Grey, H., and Chesnut, R. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo. J. Immunol., 143: 1094-1100, 1989.
28. Raychaudhuri, S., Tonks, M., Carbone, E., Ryskamp, T., Morrow, W.J., and Hanna, N. Induction of antigen-specific class I-restricted T cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA, 89: 8308-8312, 1992.
29. Parker, K., Bednarek, M., Hull, L., Utz, U., Cunningham, B., Zweerink, H., Biddison, W., and Coligan, J. Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A2. J. Immunol., 148: 3580-3587, 1992.
30. Nijman, H.W., Houbiers, J.G., Vierboom, M.P., Burg, S.H.V.D., Drijfhout, J.W., D'Amaro, J., Kenemans, P., Melief, C.J., and Kast, W.M. Identification of peptide sequences that potentially trigger HLA A2.1 restricted cytotoxic T lymphocytes. Eur. J. Immunol., 23: 1215-1219, 1993.
31. Riberdy, J., and Cresswell, P. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J. Immunol., 148: 2586-2590, 1992.
32. Trowsdale, J., Hanson, I., Mockridge, I., Beck, S., Townsend, A., and Kelly, A. Sequences encoded in the class II region of the MHC related to the ABC superfamily of transporters. Nature (Lond.), 348: 741-744, 1990.
33. Spies, T., Bresnahan, M., Bahram, S., Arnold, D., Blanck, G., Mellins, E., Pious, D., and DeMars, R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (Lond.), 348: 744-747, 1990.
34. Henderson, R., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D., and Engelhard, V. HLA-A2.1 -associated peptides from a mutant cell line: a second pathway of antigen presentation. Science (Washington DC), 255: 1264-1266, 1992.
35. Zweerink, H., Gammon, M., Utz, U., Sauma, S., Harrer, T., Hawkins, J., Johnson, R., Sirotina, A., Hermes, J., Walker, B., and Biddison, W Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol., 150: 1763-1771, 1992.
36. Kast, W., Brandt, R., Drijfhout, J., and Melief, C. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother., 14: 115-120, 1993.
37. Nijman, H., Houbiers, J., Burg, S. v. d., Vierboom, M., Kenemans, P., Kast, W., and Melief, C. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p. 3, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121-126, 1993.
38. Townsend, A., Rothbard, J., Frances, M., Gotch, G., Bahadur, J., Wrath, D., and McMichael, A. The epitopes of influenza nucleoproteins recognized by cytotoxic lymphocytes can be defined with short synthetic peptides. Cell, 44: 959-968, 1986.
39. Udaka, K., Tsomides, T., and Eisen, H. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell, 69: 989, 1992.
40. Aichele, P., Hengartner, H., Zinkernagel, R., and Schultz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med., 171: 1815-1820, 1990.
41. Miller, M., Gould-Fogerite, S., Shen, L., Woods, R., Koenig, S., Mannino, R., and Letvin, N. Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes. J. Exp. Med, 176: 1739-1744, 1992.
42. Takahashi, H., Toshiyuki, T., Morein, B., Putney, S., Germain, R., and Berzofsky, J. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (Lond.), 344: 873-875, 1990.
43. Sastry, K., Nehete, P., Venkatnarayanan, S., Morkowski, J., Platsoucas, C., and Arlinghaus, R. Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120. Virology, 188: 502-509, 1992.
44. Schulz, M., Zingkernagel, R., and Hengartner, H. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 88: 991-993, 1991.
45. Hart, M., Weinhold, K., Scearce, R., Washburn, E., Clark, C., Palker, T., and Haynes, B. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc. Natl. Acad. Sci. USA, 88: 9448-9452, 1991.
46. Nixon, D., Townsend, A., Elvin, J., Rizza, C., Gallwey, J., and McMichael, A. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (Lond.), 336: 484-487, 1988.
47. Hosmalin, A., Kumar, S., Barnd, D., Houghten, R., Smith, G., Hughes, S., and Berzofsky, J. Immunization with soluble protein-pulsed spleen cells induces class I-restricted cytotoxic T lymphocytes that recognize immunodominant epitopic peptides from Plasmodium falciparum and HIV-1. J. Immunol, 149: 1311-1318, 1992.
48. Martinon, F., Gomard, E., Hannoun, C., and Levy, J. In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides. Eur. J. Immunol, 20: 2171-2176, 1990.
49. Peace, D., Smith, J., Chen, W., You, S.G., Cosand, W., Blake, J., and Cheever, M. Lysis of ras oncogene-transformed cells by cytotoxic T lymphocytes specific for the oncogenic p. 1ras protein. J. Exp. Med, in press, 1994.
50. Cerundolo, V., Elliott, T., Elvin, J., Bastin, J., Rammensee, H., and Townsend, A. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur. J. Immunol, 21: 2069-2075, 1991.
51. Stauss, H.J., Davies, H., Sadovnikova, E., Chain, B., Horowitz, N., and Sinclair, C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA, 89: 7871-7875, 1992.
52. Carbone, F., Moore, M., Sheil, J., and Bevan, M. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med, 167: 1767-1779, 1988.
53. Lin, Y., Langman, R., and Cohn, M. The priming of cytotoxic T-cell precursors is strictly helper T cell-dependent. Scand. J. Immunol, 35: 621-626, 1992.
54. Widmann, C., Romero, P., Maryanski, J., Corradin, G., and Valmori, D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods, 155: 95-99, 1992.
55. + T cell help. J. Immunol, 147: 4069-4073, 1991.
56. Bertoletti, A., Ferrari, C., Fiaccadori, F., Penna, A., Magolskee, R., Schlicht, H., Fowler, P., Guilhot, S., and Chisari, F. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. USA, 88: 10445-10449, 1991.